Reviva Pharmaceuticals Holdings, Inc. Operating Expenses
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Operating Expenses of $2.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for the quarter ending 2026-06-30 was $2.62M, a 56.90% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for the quarter ending 2026-03-31 was $3.27M, a 49.96% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for the quarter ending 2025-12-31 was $3.56M, a 43.37% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for the quarter ending 2025-09-30 was $4.03M, a 52.38% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for fiscal 2025 was $20.20M, a 34.41% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for fiscal 2024 was $30.80M, a 22.04% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for fiscal 2023 was $39.50M, a 39.94% increase from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. operating expenses for fiscal 2022 was $28.23M, a 179.37% increase from fiscal 2021.
| Period end | Operating Expenses 2 month | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 5 month | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 8 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 11 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.62M 10-Q · filed 2026-08-12 | $5.89M 10-Q · filed 2026-08-12 | $9.45M derived: sum of 3 quarters · filed 2026-08-12 | $13.48M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2026-03-31 | $3.27M 10-Q · filed 2026-05-13 | $6.83M derived: sum of 2 quarters · filed 2026-05-13 | $10.86M derived: sum of 3 quarters · filed 2026-05-13 | $16.93M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2025-12-31 | $3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.59M derived: sum of 2 quarters · filed 2026-03-30 | $13.66M derived: sum of 3 quarters · filed 2026-08-12 | $20.20M 10-K · filed 2026-03-30 | ||||||||
| 2025-09-30 | $4.03M 10-Q · filed 2025-11-13 | $10.10M derived: sum of 2 quarters · filed 2026-08-12 | $16.64M 10-Q · filed 2025-11-13 | $22.93M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2025-06-30 | $6.07M 10-Q · filed 2026-08-12 | $12.61M 10-Q · filed 2026-08-12 | $18.90M derived: sum of 3 quarters · filed 2026-08-12 | $27.36M derived: sum of 4 quarters · filed 2026-08-12 | ||||||||
| 2025-03-31 | $6.54M 10-Q · filed 2026-05-13 | $12.82M derived: sum of 2 quarters · filed 2026-05-13 | $21.29M derived: sum of 3 quarters · filed 2026-05-13 | $29.41M derived: sum of 4 quarters · filed 2026-05-13 | ||||||||
| 2024-12-31 | $6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $14.75M derived: sum of 2 quarters · filed 2026-03-30 | $22.88M derived: sum of 3 quarters · filed 2026-03-30 | $30.80M 10-K · filed 2026-03-30 | ||||||||
| 2024-09-30 | $8.46M 10-Q · filed 2025-11-13 | $16.59M derived: sum of 2 quarters · filed 2025-11-13 | $24.51M 10-Q · filed 2025-11-13 | $34.13M derived: sum of 4 quarters · filed 2025-11-13 | ||||||||
| 2024-06-30 | $8.13M 10-Q · filed 2025-08-14 | $16.05M 10-Q · filed 2025-08-14 | $25.67M derived: sum of 3 quarters · filed 2025-08-14 | $37.24M derived: sum of 4 quarters · filed 2025-08-14 | ||||||||
| 2024-03-31 | $7.92M 10-Q · filed 2025-05-15 | $17.54M derived: sum of 2 quarters · filed 2025-05-15 | $29.11M derived: sum of 3 quarters · filed 2025-05-15 | $40.44M derived: sum of 4 quarters · filed 2025-05-15 | ||||||||
| 2023-12-31 | $9.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $21.18M derived: sum of 2 quarters · filed 2025-04-03 | $32.52M derived: sum of 3 quarters · filed 2025-04-03 | $39.50M 10-K · filed 2025-04-03 | ||||||||
| 2023-09-30 | $11.56M 10-Q · filed 2024-11-14 | $10.71M 10-Q · filed 2023-11-14 | $22.90M derived: sum of 2 quarters · filed 2024-11-14 | $29.88M 10-Q · filed 2024-11-14 | $29.52M 10-Q · filed 2023-11-14 | $38.78M derived: sum of 4 quarters · filed 2024-11-14 | ||||||
| 2023-06-30 | $11.34M 10-Q · filed 2024-08-14 | $12.07M 10-Q · filed 2023-08-14 | $18.32M 10-Q · filed 2024-08-14 | $18.81M 10-Q · filed 2023-08-14 | $27.21M derived: sum of 3 quarters · filed 2024-08-14 | $32.71M derived: sum of 4 quarters · filed 2024-08-14 | ||||||
| 2023-03-31 | $6.98M 10-Q · filed 2024-05-14 | $6.74M 10-Q · filed 2023-05-15 | $15.88M derived: sum of 2 quarters · filed 2024-05-14 | $21.38M derived: sum of 3 quarters · filed 2024-05-14 | $26.89M derived: sum of 4 quarters · filed 2024-05-14 | |||||||
| 2022-12-31 | $8.89M derived: 10-K 12 month − 10-K 9 month · filed 2024-04-15 | $14.39M derived: sum of 2 quarters · filed 2024-04-15 | $19.91M derived: sum of 3 quarters · filed 2024-04-15 | $28.23M 10-K · filed 2024-04-15 | $24.31M 10-K · filed 2023-03-30 | |||||||
| 2022-09-30 | $5.50M 10-K · filed 2024-04-15 | $3.56M 10-Q · filed 2022-11-14 | $11.02M derived: sum of 2 quarters · filed 2024-04-15 | $19.34M 10-K · filed 2024-04-15 | $16.53M 10-Q · filed 2022-11-14 | $22.43M derived: sum of 4 quarters · filed 2024-04-15 | ||||||
| 2022-06-30 | $5.52M 10-Q · filed 2023-08-14 | $12.97M 10-Q · filed 2023-08-14 | $16.93M derived: sum of 3 quarters · filed 2023-08-14 | $19.41M derived: sum of 4 quarters · filed 2023-08-14 | ||||||||
| 2022-03-31 | $7.45M 10-Q · filed 2023-05-15 | $11.41M derived: sum of 2 quarters · filed 2023-05-15 | $13.89M derived: sum of 3 quarters · filed 2023-05-15 | $15.68M derived: sum of 4 quarters · filed 2023-05-15 | ||||||||
| 2021-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $6.44M derived: sum of 2 quarters · filed 2023-03-30 | $8.23M derived: sum of 3 quarters · filed 2023-03-30 | $10.10M 10-K · filed 2023-03-30 | ||||||||
| 2021-12-13 | $10.10M 10-K · filed 2022-03-15 | |||||||||||
| 2021-09-30 | $2.48M 10-Q · filed 2022-11-14 | $4.27M derived: sum of 2 quarters · filed 2022-11-14 | $6.14M 10-Q · filed 2022-11-14 | $6.67M derived: sum of 4 quarters · filed 2022-11-14 | ||||||||
| 2021-06-30 | $1.79M 10-Q · filed 2022-08-15 | $3.66M 10-Q · filed 2022-08-15 | $4.19M derived: sum of 3 quarters · filed 2022-08-15 | |||||||||
| 2021-03-31 | $1.87M 10-Q · filed 2022-05-16 | $2.40M derived: sum of 2 quarters · filed 2022-05-16 | ||||||||||
| 2020-12-31 | $526.70K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $2.43M 10-K · filed 2022-03-15 | ||||||||||
| 2020-11-30 | $352.01K 10-Q · filed 2021-01-14 | $1.14M 10-Q · filed 2021-01-14 | ||||||||||
| 2020-09-30 | $512.29K 10-Q · filed 2021-11-15 | $1.91M 10-Q · filed 2021-11-15 | ||||||||||
| 2020-08-31 | $525.92K 10-Q · filed 2020-10-14 | $790.87K 10-Q · filed 2020-10-14 | ||||||||||
| 2020-06-30 | $777.38K 10-Q · filed 2021-08-16 | $1.40M 10-Q · filed 2021-08-16 | ||||||||||
| 2020-05-31 | $264.94K 10-Q · filed 2020-07-07 | |||||||||||
| 2020-03-31 | $618.28K 10-Q · filed 2021-05-17 | |||||||||||
| 2020-02-29 | $393.47K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04 | $559.50K derived: sum of 2 quarters · filed 2021-01-14 | $653.61K derived: sum of 3 quarters · filed 2021-01-14 | $724.74K 10-K · filed 2020-05-04 | ||||||||
| 2019-12-31 | $376.86K 10-K/A · filed 2021-05-07 | |||||||||||
| 2019-11-30 | $166.02K 10-Q · filed 2021-01-14 | $260.13K derived: sum of 2 quarters · filed 2021-01-14 | $331.27K 10-Q · filed 2021-01-14 | |||||||||
| 2019-08-31 | $94.11K 10-Q · filed 2020-10-14 | $165.25K 10-Q · filed 2020-10-14 | ||||||||||
| 2019-05-31 | $71.14K 10-Q · filed 2020-07-07 | |||||||||||
| 2019-02-28 | $152.79K 10-K · filed 2020-05-04 | |||||||||||
| 2018-11-30 | $79.15K 10-Q · filed 2020-01-10 | $79.15K 10-Q · filed 2019-01-09 | $81.47K derived: sum of 2 quarters · filed 2020-01-10 | $94.81K 10-Q · filed 2020-01-10 | ||||||||
| 2018-08-31 | $2.33K 10-Q · filed 2019-10-08 | $15.67K 10-Q · filed 2019-10-08 | ||||||||||
| 2018-05-31 | $13.34K 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |